A view of the epidemiologic landscape: how population-based studies can lend novel insights regarding the pathophysiology of glioblastoma. Chin Clin Oncol 2021 Aug;10(4):35
Date
04/14/2020Pubmed ID
32279523DOI
10.21037/cco.2020.02.07Scopus ID
2-s2.0-85113495737 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Glioblastoma is an aggressive disease that is difficult to treat, in large part due to the high level of molecular heterogeneity that limits the utility of targeted therapies. As such, population studies have been essential in characterizing the factors that promote survival. In this review, we summarize the findings in these studies. Demographic trends, molecular markers (IDH mutation, MGMT promoter methylation, TERT promoter mutation, chromosome 1p19q codeletion, PTEN, and p53 among others), radiographic correlates (peritumoral edema, enhancement, cyst formation, necrosis, and invasion among others), nonsteroidal anti-inflammatory drug (NSAID) and statin use, and ketogenic diet have been assessed. Overall, studies have found that IDH mutation and MGMT promoter methylation are positive prognostic markers and TERT is a negative prognostic marker, although subgroup analysis has revealed differential responses. NSAID and statin use have also suggested improved survival reaching significance in some studies. Ketogenic diet has not yet been adequately assessed. Further studies to characterize the interplay of these and other genetic and environmental factors are warranted.
Author List
Tadipatri R, Lyon K, Azadi A, Fonkem EAuthor
Ekokobe Fonkem DO Chair, Professor in the Neurology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Biomarkers, TumorBrain Neoplasms
DNA Methylation
DNA Modification Methylases
DNA Repair Enzymes
Glioblastoma
Humans
Isocitrate Dehydrogenase
Prognosis
